Compare IBEX & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBEX | AVTX |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 376.6M | 328.4M |
| IPO Year | 2017 | 2015 |
| Metric | IBEX | AVTX |
|---|---|---|
| Price | $32.47 | $20.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $35.00 | ★ $40.57 |
| AVG Volume (30 Days) | 100.5K | ★ 1.8M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 28.26 | ★ 72.07 |
| EPS | ★ 2.54 | N/A |
| Revenue | ★ $558,273,000.00 | $27,813,137.00 |
| Revenue This Year | $14.13 | N/A |
| Revenue Next Year | $5.68 | N/A |
| P/E Ratio | $12.85 | ★ N/A |
| Revenue Growth | 9.77 | ★ 2312.27 |
| 52 Week Low | $25.94 | $3.39 |
| 52 Week High | $42.99 | $24.27 |
| Indicator | IBEX | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 70.66 | 64.19 |
| Support Level | $27.56 | $13.47 |
| Resistance Level | $39.65 | N/A |
| Average True Range (ATR) | 1.21 | 1.85 |
| MACD | 0.56 | 0.90 |
| Stochastic Oscillator | 82.61 | 63.56 |
IBEX Ltd delivers innovative business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage, and retain valuable customers. It is an end-to-end provider of technology-enabled customer lifecycle experience (CLX) solutions to optimize customer acquisition, engagement, expansion, and experience for its clients. IBEX operates through the Business process outsourcing segment. Its services cover three areas: Digital and omni-channel Customer Experience (ibex Connect), Digital Marketing and E-Commerce (ibex Digital) and Digital CX surveys and analytics (ibex CX). It caters to a broad range of industries, such as telecommunications, cable, financial services, and healthcare.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.